Wanted to let everyone in on this gem...

Resistance @ .11 and it is set to rally.  I have held off on purchasing and today I executed my order for 4000 shares.  Just give it a look...They will get FDA approval on Oct. 15th.

NEXM - New Stock Featured in the "Micro-Cap Stocks" Section
Tue, 09/16/2008 - 01:38 — Breakout Investments

NexMed (NEXM), an innovative drug developer, is focused on leveraging its proprietary NexACT® drug delivery technology to produce new medical treatments. The company offers large pharmaceutical companies the opportunity to incorporate NexACT® into their existing drugs, allowing these companies to save considerably on R&D costs while developing new patient-friendly transdermal products and extending patent lifespans and brand equity.

The stock recently fell 92.5% after the company announced it would not be submitting a new drug application at this time for NM100060 because of first interpretable results. The way investors reacted, one would have thought they submitted it, were denied and all the R&D effort went down the tubes! But they haven't been denied and never said that they don't plan to submit the application at a later date. In fact, we believe they fully intend to as it would mean share compensation for five insiders.

In a recent article published by Bloomberg, CEO Vivian Liu said, "If you look at our cash on hand, potential milestone payments and our existing partnerships, we are undervalued." In just one month from today, the company will be meeting with the FDA to possibly allow them to resubmit an application, which could trigger as much as $10 million in milestone payments in the next 13 months. They are also poised to receive $3.5 million as soon as they are granted a patent that was expected weeks ago but has been delayed because of the patent office's backlog.

The CEO also said that the company expects approval for their topical treatment for erectile dysfunction to be approved in Canada at the end of this year or early 2009. She even revealed that they are already in talks with a potential partner. Also coming up in two days is their presentation at the EADV Annual Conference in France, where participants come together to discover the latest developments in the pharmaceutical field and find opportunities to network.

Looking at the stock itself, right now it is trading at a market cap of only $10.24 million. Southpoint Capital Advisors (a beneficial owner) recently added 6.3million shares to their position at $0.25 a share, showing strong confidence that this is only a temporary dip. Additionally, in today's trading near close several large block buys were executed, hinting that institutions may be accumulating and believe the bottom is in.

With all this potential and such a huge overreaction, this stock is "undervalued" as CEO Liue puts it; and with only 70 million shares in the float, this stock could move powerfully on any positive news. Keep this stock on strong watch this week as a chart formation forms an apex that could cause a breakout!

Last edited by jordano44 (2008-09-17 10:53:00)